Vera posts positive Phase 3 rare kidney disease data, but crowded market looms

Vera Therapeutics’ rare kidney disease candidate atacicept appears to have pulled off an unusual trick: being more effective in Phase 3 than it was in Phase 2. In the pivotal ORIGIN 3 trial in the ...